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As the COVID-19 pandemic drags on, where
have all the STEMIs gone?

To the Editor,
In the midst of current pandemic individuals with all sorts of
medical ailments are afraid to venture into health-care settings
and risk contracting Coronavirus disease 2019 (COVID-19). Irrespective of the inherent thromboembolic risks associated with
COVID-19, this puts patients at high risk of cardiac complications.
A 36-year-old male was brought to the emergency department
(ED) after being found unresponsive at home. History was limited,
given his condition. He was last seen normal over 15 h ago. He had
no significant past or family medical history. He denied any use of
alcohol or smoking. In the ED, he was febrile (101.2F°) and
hypotensive 78/59 mm Hg. His oxygen saturation (SaO2) was
78%. Laboratory investigations revealed leukocytosis (16,760/uL),
elevated d-dimer of 48,648 ng/mL (normal < 0.50 ng/ml) and
serum troponin-T (TnT) of 1.86 ng/L, which peaked to 44.4 ng/L
(normal < 0.10 ng/L). Electrocardiogram revealed ST-segment elevation in the anteroseptal leads (V2-V4). (Fig. 1) Transthoracic
echocardiography (TTE) showed extensive septal, anterior and apical akinesia with an apical left ventricular (LV) thrombus and a
reduced ejection fraction of 35%. (Fig. 2) He was intubated for
hypoxia and was started on norepinephrine infusion for hypotension. His chest x-ray and computed tomography showed multifocal
infiltrates. He received aspirin, clopidogrel, atorvastatin and a

heparin infusion for a presumed subacute ST-segment elevation
myocardial infarction (STEMI). The following day his nasal swab
test for real-time polymerase chain reaction (RT-PCR) returned
positive for acute respiratory syndrome coronavirus-2 (SARSCoV-2). He was treated with an 80 mg single dose of tocilizumab
and hydroxychloroquine 400 mg twice a day on the first day followed by 200 mg twice a day for the next 4 days. Post-extubation,
he revealed that he had been having substernal chest pain for

Fig. 2. TEE, apical view showing an apical thrombus (arrow).

Fig. 1. EKG showing ST-elevation in leads v2-v4 indicating anteroseptal wall myocardial infarction.
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Fig. 3. A. Angiography demonstrating left anterior descending artery occlusion (arrow), B. with an adequate restoration of blood flow post-stenting.

several hours before losing consciousness but had not sought care
earlier due to fear of getting COVID-19 in the hospital. He refused
further workup and was discharged home with a plan to continue
aspirin, clopidogrel, atorvastatin in addition to carvedilol and
lisinopril post-discharge. A week later, he had an elective left-sided
angiography demonstrating a 99% occlusion of the left anterior
descending artery (LAD), a drug-eluting stent was deployed with
an adequate restoration of blood flow. (Fig. 3) He was advised to
be compliant with his medications and subsequent cardiology follow-ups.
The novel Coronavirus Disease 2019 (COVID-19) is a generation-defining global pandemic; the scale, scope and pace of which
is unprecedented. Despite the high rate of cardiovascular complications, contemporary reports show that COVID-19 concerns have
prompted patients to delay seeking emergent care, reducing the
number of STEMI cases.[1,2] This is presumptively being attributed
to patients being reluctant to go to the hospital even in dire circumstances and possibly underdiagnosis in overwhelmed ED’s,
the former being the case in our patient. [1]
Recently, a United States (US) model from 9 major centers
observed a 38% drop in total STEMI activations.[3] This is similar
to a 40% reduction noted in Spain.[4] The early Hong Kong experience demonstrated a significant delay in the time of symptom
onset to the first medical encounter by about 318 min.[2] These
findings are particularly concerning given that COVID-19 itself
can be a cause of STEMI due to microthrombi, cytokine storm,
coronary spasm, or direct endothelial injury, furthermore acute
coronary syndrome occurring in COVID-19 patients has been associated with a worse prognosis. [5,6] Reluctance to visit a hospital
due to fear of morbidity related to COVID-19 only adds to time
delays in managing STEMI due to increased precautionary measures and accessory testing in the ED, delayed triaging, short staffing and slow activation of cardiac catheterization labs, putting
patients at risk of worse clinical outcomes.[2]
The specific treatment protocols for STEMI patients with
COVID-19 have been evolving. Early recommendations from the
Wuhan experience included intravenous thrombolysis as first-line
therapy for STEMI patients with confirmed COVID-19 given that
most hospitals do not have protected cardiac catheterization labs
and coronary care units for respiratory borne illnesses.[7] More
recently, the Society of Cardiovascular Angiography and Intervention (SCAI) recommendations favored continuation of the current
standard of care (percutaneous intervention) in COVID-19 patients,
though recognize that this may change if hospital systems become
further overwhelmed.[8]

In our case, the collision between COVID-19 induced STEMI and
a reluctance to seek urgent care led to catastrophic complications.
The reduced ejection fraction, cardiogenic shock and the early
development of an LV thrombus seen in this case can be attributed
to not only the late presentation but perhaps also a consequence of
COVID-19 specific hypercoagulable state. Elevated D-dimer, raised
troponin levels and EKG abnormalities prompted a high suspicion
for ACS even in a hitherto healthy person with no conventional cardiovascular risk factors.
While remarkable public health efforts are ongoing, we advocate for increased public awareness of cardiovascular complications of COVID-19 and the need to seek early medical attention.
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